LY6G6F-LY6G6D

Across TCGA pan-cancer cohorts, LY6G6F-LY6G6D Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LY6G6F-LY6G6D data layer compared with 17 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher LY6G6F-LY6G6D Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LY6G6F-LY6G6D expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

SARC, BLCA, and SKCM are the cancer types where LY6G6F-LY6G6D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.101	0.632	.011	12	view →
BLCA	OS	Median	II,III,IV	1.000	0.413	.037	6	view →
SKCM	OS	Median	All	0.240	0.343	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LY6G6F-LY6G6D–SARC (DFS)

Open the SARC breakdown →